Glucagon-like peptide-1 (GLP-1) receptor agonists are a promising new therapeutic potential of metabolic diseases, including MASLD, type 2 diabetes mellitus (T2DM) and cardiovascular disorders [104]. This evidence concerns the gene GCG and type 2 diabetes mellitus.